X4 Pharmaceuticals (XFOR) Tops Q2 EPS by 6c
Tweet
Share
E-mailGet Alerts XFOR Hot Sheet
Join SI Premium – FREE
X4 Pharmaceuticals (NASDAQ: XFOR) reported Q2 EPS of ($0.13), $0.06 better than the analyst estimate of ($0.19). Revenue for the quarter came in at $8.81 million versus the consensus estimate of $2.28 million.
For earnings history and earnings-related data on X4 Pharmaceuticals (XFOR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Wolfe Research Upgrades Abbvie (ABBV) to Outperform
- Wolfe Research Downgrades Stryker (SYK) to Peerperform
- Birkenstock Holding (BIRK) Misses Q3 EPS by 2c; lifts guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
